Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
Open Access
- 16 August 2016
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 115 (6) , 691-702
Abstract
Background: To assess antivascular effects, and evaluate clinically translatable magnetic resonance imaging (MRI) biomarkers of tumour response in vivo, following treatment with vanucizumab, a bispecific human antibody against angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Methods: Colo205 colon cancer xenografts were imaged before and 5 days after treatment with a single 10 mg kg−1 dose of either vanucizumab, bevacizumab (anti-human VEGF-A), LC06 (anti-murine/human Ang-2) or omalizumab (anti-human IgE control). Volumetric response was assessed using T2-weighted MRI, and diffusion-weighted, dynamic contrast-enhanced (DCE) and susceptibility contrast MRI used to quantify tumour water diffusivity (apparent diffusion coefficient (ADC), × 106 mm2 s−1), vascular perfusion/permeability (Ktrans, min−1) and fractional blood volume (fBV, %) respectively. Pathological correlates were sought, and preliminary gene expression profiling performed. Results: Treatment with vanucizumab, bevacizumab or LC06 induced a significant (PKtrans (PPP<0.05) reduction in Hoechst 33342 uptake compared with control. Gene expression profiling identified 20 human genes exclusively regulated by vanucizumab, 6 of which are known to be involved in vasculogenesis and angiogenesis. Conclusions: Vanucizumab is a promising antitumour and antiangiogenic treatment, whose antivascular activity can be monitored using DCE and susceptibility contrast MRI. Differential gene expression in vanucizumab-treated tumours is regulated by the combined effect of Ang-2 and VEGF-A inhibition.Keywords
This publication has 53 references indexed in Scilit:
- The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular functionBritish Journal of Cancer, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?British Journal of Cancer, 2012
- Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot studyCancer Imaging, 2011
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectivesThe Lancet Oncology, 2008
- Mapping and quantifying mammalian transcriptomes by RNA-SeqNature Methods, 2008
- DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agentsBritish Journal of Cancer, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007